SIETES :: 93008 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

2.

Zhu H, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Starub L, Huybrechts KF. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020;369:20 de mayo. [Ref.ID 103628]

3.

Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd C, Criner GJ, Donaldson GC, Dreher M, Fan VS, Gershon AS, et al.. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline . Am J Respir Crit Care Med 2020;201:1 de mayo. [Ref.ID 103620]

4.

Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]

5.

Samper E. Lo que el dinero no puede acelerar: ¿Por qué requiere tanto tiempo conseguir una vacuna contra el coronavirus? . eldiario.es 2020:9 de mayo. [Ref.ID 103617]

6.

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiology 2020:1 de mayo. [Ref.ID 103613]

7.

Rejón >R. El dinero público empuja la investigación contra la COVID-19 sin garantía de que las patentes farmacéuticas permitan el acceso a esas medicinas. eldiario.es 2020:1 de mayo. [Ref.ID 103610]

8.

Sakoulas G, El Sahly H, Ellison III RT. Chloroquine and hydroxychloroquine: old drugs in a new COVID-19 world. Journal Watch 2020:1. [Ref.ID 103608]

9.

Reymolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, et al.. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med 2020:1. [Ref.ID 103604]

10.

Parsons L. UPDATED: Gilead drops remdesivir’s orphan drug designation. comes amid intense public criticism of the regulatory status. PMLiVE 2020:26 de marzo. [Ref.ID 103601]

11.

Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]

12.

Di Maio M, Audisio M, Cardone C, De Luca E, Gargiulo P, Zichi C, Perrone F. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings. JAMA Oncology 2020:1. [Ref.ID 103598]

13.

Lin KJ, Dvorin E, Kesselheim AS. Prescribing systemic steroids for acute respiratory tract infections in United States outpatient settings: A nationwide population-based cohort study. PLOS Medicine 2020:31 de marzo. [Ref.ID 103587]

14.

Luo Q, Qin T. Managing clinical trials for covid-19: the importance of ethics committees. BMJ 2020;369:3 de abril. [Ref.ID 103584]

15.

Anderson TS, Odden MC, Penko J, et al.. Generalizability of clinical trials supporting the 2017 American College of Cardiology/American Heart Association blood pressure guideline. JAMA Intern Med 2020:16 de marzo. [Ref.ID 103580]

16.

Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, et al.. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020;382:2 de abril. [Ref.ID 103578]

17.

Anónimo. FDA requests removal of all ranitidine Products (Zantac) from the market FDA advises consumers, patients and health care professionals after new FDA studies show risk to public health.. U.S. Food and Drug Administration 2020:1 de abril. [Ref.ID 103577]

18.

Anónimo. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. U.S. Food and Drug Administration 2020:19 de marzo. [Ref.ID 103572]

19.

Ledley FD, McCoy SS, Vaughan G, Cleary EG. Profitability of large pharmaceutical companies compared with other large public companies. JAMA 2020;323:3 de marzo. [Ref.ID 103560]

20.

Anónimo. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. U.S. Food and Drug Administration 2020:4 de marzo. [Ref.ID 103559]